image
Healthcare - Medical - Instruments & Supplies - NYSE - CH
$ 87.78
-1.7 %
$ 43.4 B
Market Cap
39.01
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ALC stock under the worst case scenario is HIDDEN Compared to the current market price of 87.8 USD, Alcon Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ALC stock under the base case scenario is HIDDEN Compared to the current market price of 87.8 USD, Alcon Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ALC stock under the best case scenario is HIDDEN Compared to the current market price of 87.8 USD, Alcon Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ALC

image
$98.0$98.0$96.0$96.0$94.0$94.0$92.0$92.0$90.0$90.0$88.0$88.0$86.0$86.0$84.0$84.0$82.0$82.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
9.91 B REVENUE
4.82%
1.41 B OPERATING INCOME
36.00%
1.02 B NET INCOME
-2.08%
2.08 B OPERATING CASH FLOW
40.20%
-1.17 B INVESTING CASH FLOW
-6.67%
-322 M FINANCING CASH FLOW
-52.61%
2.47 B REVENUE
-1.16%
468 M OPERATING INCOME
18.48%
350 M NET INCOME
0.00%
384 M OPERATING CASH FLOW
-17.05%
-578 M INVESTING CASH FLOW
-74.22%
-96 M FINANCING CASH FLOW
-1147.09%
Balance Sheet Alcon Inc.
image
Current Assets 6.31 B
Cash & Short-Term Investments 1.83 B
Receivables 2.08 B
Other Current Assets 2.4 B
Non-Current Assets 24 B
Long-Term Investments 751 M
PP&E 4.84 B
Other Non-Current Assets 18.4 B
6.03 %6.86 %7.90 %15.94 %60.79 %Total Assets$30.3b
Current Liabilities 2.28 B
Accounts Payable 773 M
Short-Term Debt 169 M
Other Current Liabilities 1.34 B
Non-Current Liabilities 6.52 B
Long-Term Debt 4.97 B
Other Non-Current Liabilities 1.55 B
8.79 %15.19 %56.48 %17.61 %Total Liabilities$8.8b
EFFICIENCY
Earnings Waterfall Alcon Inc.
image
Revenue 9.91 B
Cost Of Revenue 4.4 B
Gross Profit 5.51 B
Operating Expenses 4.1 B
Operating Income 1.41 B
Other Expenses 395 M
Net Income 1.02 B
10b10b9b9b8b8b7b7b6b6b5b5b4b4b3b3b2b2b1b1b0010b(4b)6b(4b)1b(395m)1bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
55.61% GROSS MARGIN
55.61%
14.26% OPERATING MARGIN
14.26%
10.27% NET MARGIN
10.27%
4.72% ROE
4.72%
3.35% ROA
3.35%
4.06% ROIC
4.06%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Alcon Inc.
image
2b2b1b1b1b1b1b1b800m800m600m600m400m400m200m200m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 1.02 B
Depreciation & Amortization 1.23 B
Capital Expenditures -670 M
Stock-Based Compensation 150 M
Change in Working Capital -189 M
Others -440 M
Free Cash Flow 1.41 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Alcon Inc.
image
Wall Street analysts predict an average 1-year price target for ALC of $104 , with forecasts ranging from a low of $85 to a high of $110 .
ALC Lowest Price Target Wall Street Target
85 USD -3.17%
ALC Average Price Target Wall Street Target
104 USD 18.48%
ALC Highest Price Target Wall Street Target
110 USD 25.31%
Price
Max Price Target
Min Price Target
Average Price Target
1101101051051001009595909085858080Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.333 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.350000.350000.300000.300000.250000.250000.200000.200000.150000.150000.100000.100000.050000.050000.000000.000000.109690.110.2050.210.235740.240.264410.260.33340.332021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Alcon Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Is it Apt to Retain Alcon Stock in Your Portfolio for Now? ALC stays on investors' radar due to its Vision Care arm's performance and contributions from new products despite macro risks and stiff competition. zacks.com - 5 days ago
Alcon Canada Earns Global Recognition as a Top Employer TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that Alcon Canada has been certified as a Top Employer in Canada by the Top Employers Institute, a recognized authority on identifying excellence in people practices and workplace culture. Being certified as a Top Employer showcases Alcon Canada's commitment to building a better world of work through exceptional HR policies and forward-thinking people practices. This recog. businesswire.com - 1 week ago
Gordon Schanzlin New Vision Institute Becomes First U.S. Clinic to Use Alcon's Breakthrough Unity Phaco System Dr. Echegoyen Participated in Clinical Trials for the First Major Phacoemulsification Advancement in Over 15 Years Dr. Echegoyen Participated in Clinical Trials for the First Major Phacoemulsification Advancement in Over 15 Years globenewswire.com - 1 week ago
Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon® PanOptix® Pro intraocular lens (IOL) for cataract patients in Canada. PanOptix Pro leverages proprietary ENLIGHTEN® NXT Optical technology which delivers the lowest light scatter and highest reported light utilization of any trifocal IOL.1-3,5-9,**,‡‡ PanOptix Pro provides an unprecedented 94% light utilization, compared to a theore. businesswire.com - 2 weeks ago
LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSAR, Inc. (NasdaqCM: LNSR) to Alcon Inc. (NYSE: ALC). Under the terms of the proposed transaction, shareholders of LENSAR will receive $14.00 in cash, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash conditioned on achievement of a milestone, for each. businesswire.com - 1 month ago
Alcon Stock Rises Following the FDA Approval of TRYPTYR FDA approves ALC's TRYPTYR, a new dry eye treatment with rapid tear production. The approval is supported by strong Phase 3 trial results. zacks.com - 1 month ago
US FDA approves Alcon's new dry-eye drug Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED). reuters.com - 1 month ago
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease GENEVA--(BUSINESS WIRE)--Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease. businesswire.com - 1 month ago
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease GENEVA--(BUSINESS WIRE)--Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease. businesswire.com - 1 month ago
Turkey Contact Lens Market - Competition, Forecast & Opportunities to 2030, Featuring Tech Contactlens, Diafarma, Alcon Laboratories, Diplomat Optics, Hoya Turkiye, ZEISS Turkiye, Keralens & more The Turkish Contact Lens Market, valued at USD 55.15 Million in 2024, is set to reach USD 91.08 Million by 2030, at a CAGR of 8.68%. Growth is driven by rising vision correction awareness and demand for cosmetic lenses. The Turkish Contact Lens Market, valued at USD 55.15 Million in 2024, is set to reach USD 91.08 Million by 2030, at a CAGR of 8.68%. Growth is driven by rising vision correction awareness and demand for cosmetic lenses. globenewswire.com - 1 month ago
Alcon Inc. (ALC) Q1 2025 Earnings Call Transcript Alcon Inc. (NYSE:ALC ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Dan Cravens - Vice President, Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants Veronika Dubajova - Citi Jack Reynolds-Clark - RBC Capital Markets Graham Doyle - UBS Ryan Zimmerman - BTIG David Saxon - Needham & Company Larry Biegelsen - Wells Fargo Patrick Wood - Morgan Stanley Anthony Petrone - Mizuho Group Tom Stephan - Stifel Brett Fishbin - KeyBanc Capital Markets Young Li - Jefferies Jeff Johnson - Baird David Adlington - JPMorgan Operator Greetings, and welcome to the Alcon First Quarter 2025 Earnings Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 1 month ago
Alcon Q1 Earnings Miss Estimates, Stock Down, 2025 EPS View Lowered ALC ends the first quarter of 2025 on a disappointing note. zacks.com - 1 month ago
8. Profile Summary

Alcon Inc. ALC

image
COUNTRY CH
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 43.4 B
Dividend Yield 0.00%
Description Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Contact Chemin de Blandonnet 8, Geneva, 1214 https://www.alcon.com
IPO Date April 9, 2019
Employees 25599
Officers Margaret Buckley Chief Accounting Officer Mr. David J. Endicott Chief Executive Officer & Director Dr. Franck Leveiller SVice President of Global Research & Development and Chief Scientific Officer Mr. Muru Murugappan Senior Vice President and Chief Information & Transformation Officer Ms. Kimberly Martin Senior Vice President, Chief HR Officer & Corporate Communications Mr. Leon Sergio Duplan Fraustro Senior Vice President & President of Americas Mr. Laurent Attias SVice President of Corporate Strategy, Business Development and Licensing (BD&L), M&A Mr. Timothy C. Stonesifer Senior Vice President & Chief Financial Officer Mr. Ian Bell Senior Vice President & Chief Operating Officer Mr. Royce R. Bedward J.D. Senior Vice President, General Counsel & Corporate Secretary